Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion.
Background. Ranibizumab is approved for treatment of macular edema in eyes with retinal vein occlusion (RVO). Some eyes show low-response to treatmentwith regard to visual acuity gain (VA) andOCT central retinal thickness (CRT) reduction. The goal of this study was to quantify the percentage of low-...
| Publicado en: | Journal of Ophthalmology pp. 1 - 7 |
|---|---|
| Autores principales: | , , , |
| Formato: | diagnostic images pictorial research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |